Aphinity trial: New Progress in the treatment of HER2-positive breast cancer
Press release (04/09/2025) Aphinity trial: New Progress in the treatment of HER2-positive breast cancerBrussels, 4th of June 2025 – The final results of the APHINITY international trial, presented at the ESMO 2025 congress in Berlin, show that a targeted dual therapy significantly improves the long term survival of patients with HER2-positive breast cancers with lymph node positivity. The Jules Bordet Institute, through its…
(read more)